Obesity & OverweightPhase 4NCT07657676
Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
A Phase 4 study testing Mazdutide in people with Obesity & Overweight and Coronary Heart Disease, run by China National Center for Cardiovascular Diseases at 1 site in China.
Trial summary
This multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the effect of mazdutide, a dual GLP-1/GCG receptor agonist, on coronary plaque progression assessed by coronary computed tomography angiography (CCTA) in patients with coronary atherosclerosis and overweight or obesity. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Obesity & Overweight, Coronary Heart Disease
- What is being tested?
- Mazdutide
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 116 participants
- Where
- 1 siteChina
- Study dates
- 14 Sep 2026to 31 Dec 2027
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- BMI ≥ 28 kg/m2 or BMI≥ 24kg/m2 with at least one of the following conditions: dyslipidemia, metabolic associated fatty liver disease, hypertension, prediabetes, type 2 diabetes mellitus, or obesity-related obstructive sleep apnea syndrome (at screening or within 6 months prior to screening).
- Coronary stenosis 30-70% confirmed by CAG or CCTA within 3 months prior to enrollment.
- Signed informed consent
- Willing to comply with follow-up
Who cannot join
- History or evidence of the following :
- A history of severe hypoglycemia, or recurrent symptomatic hypoglycemia (≥2 episodes) within the past six months
- Severe heart disease as determined by the investigator, including coronary artery disease that has undergone or is planned for coronary artery bypass grafting or percutaneous coronary intervention, valvular heart disease requiring valve repair or replacement, heart transplantation, severe heart failure (NYHA III-IV) or cardiogenic shock, or a known history of left ventricular ejection fraction ≤30%
- A hemorrhagic/ischemic stroke or transient ischemic attack within six months prior to screening
- A history of acute or chronic pancreatitis, gallbladder/bile duct disease, or pancreatic injury
- Presence of severe diseases such as malignant tumors, lymphoma, liver cirrhosis, HIV-positive status, etc., with an expected survival of less than 2 years
Show all 21Show fewer
- Contraindications to GLP-1/GCG dual receptor agonists, such as hypersensitivity or severe intolerance
- A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
- Use of the following medications or treatments prior to screening :
- Use of weight-affecting medications (e.g., systemic steroids, tricyclic antidepressants, psychiatric/sedative medications, etc.) within three months prior to screening
- Use of GLP-1 RA or GIP/GLP-1 RA (exposure to investigational drugs) within three months prior to screening
- Participation in other clinical trials (exposure to investigational drugs) within three months prior to screening
- Known clinically significant abnormal gastric emptying or current use of medications that directly affect gastrointestinal motility
- Laboratory test results meeting any of the following criteria at screening (repeat testing within one week is permitted if there is a clear reason, and the reason for retesting must be documented by the investigator)
- Serum calcitonin ≥50 ng/L (pg/mL)
- ALT/AST >3.0 × ULN
- eGFR <30 mL/min/1.73m²
- Abnormal thyroid function (TSH >6 mIU/L or <0.4 mIU/L)
- Pregnancy, planned pregnancy, or breastfeeding
- Contraindications to CCTA, including severe allergy to iodine contrast agents, presence of cardiac implantable electronic devices or other metal implants that may affect image analysis
- Inability to complete the study or comply with study requirements as determined by the investigator Exclusion criteria for the PET-CT substudy: All exclusion criteria of the main study, as well as contraindications to PET-CT examination
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, 100037
Xiao Wang, MD, 86-10-88396953, wangxiao@fuwai.com
Luo Fang, 86-10-88396953, luofang@fuwaihospital.org
About this study
Official title: Effect of Mazdutide on Coronary Plaque Progression in Patients With Coronary Atherosclerosis and Overweight or Obesity: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial
This multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the effect of mazdutide, a dual GLP-1/GCG receptor agonist, on coronary plaque progression assessed by coronary computed tomography angiography (CCTA) in patients with coronary atherosclerosis and overweight or obesity. The primary endpoint is the change in total non-calcified plaque volume (NCPV) from baseline to week 52. Secondary endpoints include changes in pericoronary adipose tissue inflammation (fat attenuation index, FAI), plaque composition, metabolic parameters, inflammatory biomarkers, and clinical outcomes. A substudy will include 18F-NaF PET/CT imaging.
Read the detailed description
Coronary atherosclerosis is the principal pathological substrate underlying most cardiovascular events and remains a leading cause of morbidity and mortality. Overweight and obesity are well-established independent risk factors that drive the development and progression of coronary atherosclerotic plaque, and thus represent critical modifiable targets for therapeutic intervention.
Prior studies have shown that GLP-1 receptor agonists (GLP-1RAs) provide hypoglycemic, weight-loss, and cardiovascular protective benefits. Mazdutide, the first approved GLP-1/GCG dual receptor agonist, combines GLP-1-mediated insulin secretion and appetite suppression with GCG-driven energy expenditure. Phase III trials have demonstrated robust glycemic and weight benefits, along with reductions in hs-CRP and liver fat. Given that dual-receptor activation yields more robust metabolic improvements than single-receptor agonism, mazdutide may possess greater potential than GLP-1 monotherapy in suppressing coronary plaque progression.
Therefore, we propose a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of 52 weeks of Mazdutide treatment on CCTA-assessed non-calcified plaque volume (NCPV) in patients with coronary atherosclerosis and overweight or obesity.
PET-CT substudy: A subset of eligible patients will be enrolled into a sub-study, we aim to evaluate the efficacy of Mazdutide on plaque inflammation assessed by 18F-NaF PET/CT.
- Conditions
- Obesity & Overweight, Coronary Heart Disease
- Being tested
- Mazdutide, Placebo
- Keywords
- GLP-1RA, CCTA, Mazdutide, Obesity, Plaque, Overweight, Coronary Heart Disease
- Medical subject headings
- Obesity, Overweight, Coronary Disease, Plaque, Amyloid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MazdutideDrug
Mazdutide administered subcutaneously once weekly, starting at 2 mg for 4 weeks, then escalated to 4 mg for 4 weeks, and then to 6 mg thereafter until week 52.
PlaceboDrug
Placebo administered subcutaneously once weekly, starting at 2 mg for 4 weeks, then escalated to 4 mg for 4 weeks, and then to 6 mg thereafter until week 52.
| Study group | Role | What they receive |
|---|---|---|
| Experimental: Mazdutide | Experimental | Not described Receives: Drug: Mazdutide |
| Placebo | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in total non-calcified plaque volume (NCPV) by CCTA from baseline to 52 weeks
Measured: Baseline and 52 weeks
Secondary outcomes (28)
Change in RCA pericoronary fat attenuation index (RCA-FAI) by CCTA from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in LAD pericoronary fat attenuation index (LAD-FAI) by CCTA from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in LCX pericoronary fat attenuation index (LCX-FAI) by CCTA from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in lesion pericoronary fat attenuation index (lesion-FAI) by CCTA from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in total plaque volume (TPV) by CCTA from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in percent atheroma volume (PAV) by CCTA from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in low-attenuation plaque volumes by CCTA from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in fibrous plaque volumes by CCTA from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in fibrofatty plaque volumes by CCTA from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in calcified plaque volumes by CCTA from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in total cholesterol from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in triglycerides from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in LDL-C from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in non-HDL-C from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in ApoB from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in HbA1c from baseline to 52 weeks
Measured: Baseline and 52 weeks
Changein fasting glucose from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in uric acid from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in Lp(a) from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in hs-CRP from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in IL-6 from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in TNF-α from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in body weight from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in waist circumference from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in waist-to-hip ratio from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in SBP from baseline to 52 weeks
Measured: Baseline and 52 weeks
Change in DBP from baseline to 52 weeks
Measured: Baseline and 52 weeks
Incidence of major adverse cardiovascular events (MACE) at 52 weeks
Measured: Baseline and 52 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jun 2026
- Study start14 Sep 2026
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obesity & OverweightStudies of the same condition, open and under way.
- More trials run by China National Center for Cardiovascular DiseasesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 116 participants (estimated)
Sponsor and investigators
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Xiao Wang, China National Center for Cardiovascular Diseases
- Investigators
- Ke fei Dou, Principal investigator, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeXiao Wang, Principal investigator, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07657676
- Sponsor's protocol ID
- 2026-3068
- Status last verified
- Oct 2026
- First submitted
- 14 Jun 2026
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Mazdutide on Coronary Plaque Progression in Patients With Coronary Atherosclerosis and Overweight or Obesity: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial
- ClinicalTrials.gov ID
- NCT07657676
- Acronym / sponsor ID
- 2026-3068
- Conditions
- Obesity & Overweight, Coronary Heart Disease
- Keywords
- GLP-1RA, CCTA, Mazdutide, Obesity, Plaque, Overweight, Coronary Heart Disease
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 116 participants (estimated)
- Lead sponsor
- China National Center for Cardiovascular DiseasesOther government
- Study start
- 14 Sep 2026 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 18 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the effect of mazdutide, a dual GLP-1/GCG receptor agonist, on coronary plaque progression assessed by coronary computed tomography angiography (CCTA) in patients with coronary atherosclerosis and overweight or obesity. The primary endpoint is the change in total non-calcified plaque volume (NCPV) from baseline to week 52. Secondary endpoints include changes in pericoronary adipose tissue inflammation (fat attenuation index, FAI), plaque composition, metabolic parameters, inflammatory biomarkers, and clinical outcomes. A substudy will include 18F-NaF PET/CT imaging.
Detailed description
Coronary atherosclerosis is the principal pathological substrate underlying most cardiovascular events and remains a leading cause of morbidity and mortality. Overweight and obesity are well-established independent risk factors that drive the development and progression of coronary atherosclerotic plaque, and thus represent critical modifiable targets for therapeutic intervention.
Prior studies have shown that GLP-1 receptor agonists (GLP-1RAs) provide hypoglycemic, weight-loss, and cardiovascular protective benefits. Mazdutide, the first approved GLP-1/GCG dual receptor agonist, combines GLP-1-mediated insulin secretion and appetite suppression with GCG-driven energy expenditure. Phase III trials have demonstrated robust glycemic and weight benefits, along with reductions in hs-CRP and liver fat. Given that dual-receptor activation yields more robust metabolic improvements than single-receptor agonism, mazdutide may possess greater potential than GLP-1 monotherapy in suppressing coronary plaque progression.
Therefore, we propose a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of 52 weeks of Mazdutide treatment on CCTA-assessed non-calcified plaque volume (NCPV) in patients with coronary atherosclerosis and overweight or obesity.
PET-CT substudy: A subset of eligible patients will be enrolled into a sub-study, we aim to evaluate the efficacy of Mazdutide on plaque inflammation assessed by 18F-NaF PET/CT.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental: Mazdutide | Experimental | Drug: Mazdutide |
| Placebo | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age ≥ 18 years
- BMI ≥ 28 kg/m2 or BMI≥ 24kg/m2 with at least one of the following conditions: dyslipidemia, metabolic associated fatty liver disease, hypertension, prediabetes, type 2 diabetes mellitus, or obesity-related obstructive sleep apnea syndrome (at screening or within 6 months prior to screening).
- Coronary stenosis 30-70% confirmed by CAG or CCTA within 3 months prior to enrollment.
- Signed informed consent
- Willing to comply with follow-up
Key exclusion criteria (21 listed)
- History or evidence of the following :
- Use of the following medications or treatments prior to screening :
- Laboratory test results meeting any of the following criteria at screening (repeat testing within one week is permitted if there is a clear reason, and the reason for retesting must be documented by the investigator)
- Pregnancy, planned pregnancy, or breastfeeding
- Contraindications to CCTA, including severe allergy to iodine contrast agents, presence of cardiac implantable electronic devices or other metal implants that may affect image analysis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MazdutideMazdutide administered subcutaneously once weekly, starting at 2 mg for 4 weeks, then escalated to 4 mg for 4 weeks, and then to 6 mg thereafter until week 52. | Drug | Experimental: Mazdutide |
| PlaceboPlacebo administered subcutaneously once weekly, starting at 2 mg for 4 weeks, then escalated to 4 mg for 4 weeks, and then to 6 mg thereafter until week 52. | Drug | Placebo |
Primary outcome
Change in total non-calcified plaque volume (NCPV) by CCTA from baseline to 52 weeks
Time frame: Baseline and 52 weeks
28 secondary outcomes
Change in RCA pericoronary fat attenuation index (RCA-FAI) by CCTA from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in LAD pericoronary fat attenuation index (LAD-FAI) by CCTA from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in LCX pericoronary fat attenuation index (LCX-FAI) by CCTA from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in lesion pericoronary fat attenuation index (lesion-FAI) by CCTA from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in total plaque volume (TPV) by CCTA from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in percent atheroma volume (PAV) by CCTA from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in low-attenuation plaque volumes by CCTA from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in fibrous plaque volumes by CCTA from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in fibrofatty plaque volumes by CCTA from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in calcified plaque volumes by CCTA from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in total cholesterol from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in triglycerides from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in LDL-C from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in non-HDL-C from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in ApoB from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in HbA1c from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Changein fasting glucose from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in uric acid from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in Lp(a) from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in hs-CRP from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in IL-6 from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in TNF-α from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in body weight from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in waist circumference from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in waist-to-hip ratio from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in SBP from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Change in DBP from baseline to 52 weeks
Time frame: Baseline and 52 weeks
Incidence of major adverse cardiovascular events (MACE) at 52 weeks
Time frame: Baseline and 52 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Obesity & Overweight
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ke fei Dou principal investigator
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
Xiao Wang principal investigator
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Mazdutide in people with Obesity & Overweight and Coronary Heart Disease, run by China National Center for Cardiovascular Diseases at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xiao Wang (86-10-88396953, wangxiao@fuwai.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in total non-calcified plaque volume (NCPV) by CCTA from baseline to 52 weeks (time frame: Baseline and 52 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.